A price revision is in the offing in the diagnostics sector where rates have largely remained stable the past few years. With new entrants, primarily online players that had kept rates low, choosing to revise prices, the incumbents too have sensed an opportunity to do so.
Diagnostics players were absorbing the rise in costs through scale (of business), Om Manchanda, managing director, Dr Lal PathLabs, tells Business Standard. “But now the Covid-19 volumes are gone, and so it is back to the pre-Covid business,” he says. “However, raising the cost of routine tests is still difficult. For some high-end and